We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

91 hedge funds and large institutions have $152M invested in Cascadian Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,900% more call options, than puts

Call options by funds: $50K | Put options by funds: $1K

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

15% more funds holding

Funds holding: 79 → 91 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less capital invested

Capital invested by funds: $166M → $152M (-$14.1M)

Holders
91
Holders Change
+12
Holders Change %
+15.19%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
30
Reduced
19
Closed
5
Calls
$50K
Puts
$1K
Net Calls
+$49K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.95M
2
ACA
Avoro Capital Advisors
New York
+$2.72M
3
PC
Polar Capital
United Kingdom
+$2.66M
4
Goldman Sachs
Goldman Sachs
New York
+$2.53M
5
KCM
Kennedy Capital Management
Missouri
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$12.3M
2
RG
Redmile Group
California
-$5.41M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$170K
5
PAWC
P.A.W. Capital
Connecticut
-$164K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$493K +$180K +43,915 +49%
Millennium Management
27
Millennium Management
New York
$419K +$209K +51,000 +82%
DCM
28
DAFNA Capital Management
California
$395K -$43K -10,500 -9%
UC
29
Unterberg Capital
New York
$370K +$409K +100,000 New
TCIM
30
TIAA CREF Investment Management
New York
$334K -$24K -5,863 -6%
Morgan Stanley
31
Morgan Stanley
New York
$330K +$117K +28,692 +48%
Handelsbanken Fonder
32
Handelsbanken Fonder
Sweden
$311K – – –
Renaissance Technologies
33
Renaissance Technologies
New York
$302K +$73.3K +17,900 +28%
Deutsche Bank
34
Deutsche Bank
Germany
$299K -$1M -244,491 -75%
PCM
35
Prelude Capital Management
New York
$293K +$324K +79,155 New
Connor, Clark & Lunn Investment Management (CC&L)
36
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$270K -$8.19K -2,000 -3%
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
$238K +$264K +64,425 New
TA
38
Teachers Advisors
New York
$228K – – –
Charles Schwab
39
Charles Schwab
California
$224K – – –
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$212K +$164K +40,080 +234%
AA
41
ALPS Advisors
Colorado
$207K +$229K +56,018 New
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$205K -$3.32K -811 -1%
Bank of America
43
Bank of America
North Carolina
$184K +$43.8K +10,688 +27%
BTS
44
BB&T Securities
Virginia
$181K -$3.41K -833 -2%
Two Sigma Investments
45
Two Sigma Investments
New York
$181K +$200K +48,835 New
SG Americas Securities
46
SG Americas Securities
New York
$143K +$104K +25,464 +195%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$135K – – –
PCM
48
Perkins Capital Management
Minnesota
$132K -$64.2K -15,681 -31%
ProShare Advisors
49
ProShare Advisors
Maryland
$120K +$133K +32,469 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$118K -$29.7K -7,254 -19%
1
2
3 4

CASC Hedge Fund Activity: Q4 2017 in Review

91 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2017, worth a combined $152M — down 8.5% from $166M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CASC positions and 5 closed out — a net gain of 13 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $2.95M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $12.3M sold.

  • 91 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $152M of Cascadian Therapeutics, Inc. stock for Q4 2017, down 8.5% quarter-over-quarter.
  • 18 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2017 and 5 closed out, a net change of +13 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q4 2017 was BlackRock, an estimated $2.95M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q4 2017 was EcoR1 Capital, an estimated $12.3M sold.

Based on aggregated 13F filings for Q4 2017.